Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort

Virchows Archiv

Volumn 457, Issue 5, 2010, Pages 547-553

  Rajab, Ramzi ^a   Fisher, Gabrielle ^a   Kattan, Michael W ^b   Foster, Christopher S ^c   Oliver, Tim ^a   Møller, Henrik ^d   Reuter, Victor ^e   Scardino, Peter ^e   Cuzick, Jack ^a   Berney, Daniel M ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Biopsy prognostic factors; Prostate biopsy; Prostate cancer; Tumour extent

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER INVASION; CANCER SURVIVAL; COHORT ANALYSIS; CONSERVATIVE TREATMENT; DEATH; GLEASON SCORE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; BIOPSY, NEEDLE; COHORT STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PATHOLOGY, SURGICAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 78149443844     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-010-0971-z     Document Type: Article

References (44)

1. AE Pelzer D Colleselli J Bektic, et al. 2008 Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference? BJU Int 102 24 27 10.1111/j.1464-410X.2008.07566.x 18341623 (Pubitemid 351799445)
2. DS Smith PA Humphrey WJ Catalona 1997 The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience Cancer 80 1852 1856 10.1002/(SICI)1097-0142(19971101)80:9<1852::AID- CNCR25>3.0.CO;2-3 9351559 1:STN:280:DyaK1c%2FhtF2htg%3D%3D (Pubitemid 27475948)
3. G Bartsch W Horninger H Klocker, et al. 2008 Tyrol prostate cancer demonstration project: early detection, treatment, outcome, incidence and mortality BJU Int 101 809 816 10.1111/j.1464-410X.2008.07502.x 18321314 1:CAS:528:DC%2BD1cXltlOjt7c%3D (Pubitemid 351347736)
4. S Loeb KA Roehl BT Helfand, et al. 2008 Complications of open radical retropubic prostatectomy in potential candidates for active monitoring Urology 72 887 891 10.1016/j.urology.2007.12.016 18329080
5. DV Makarov BJ Trock EB Humphreys, et al. 2007 Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005 Urology 69 1095 1101 10.1016/j.urology.2007.03.042 17572194 (Pubitemid 46891611)
6. J Cuzick G Fisher MW Kattan, et al. 2006 Long-term outcome among men with conservatively treated localised prostate cancer Br J Cancer 95 1186 1194 10.1038/sj.bjc.6603411 17077805 1:STN:280:DC%2BD28nktlSjtg%3D%3D (Pubitemid 44658482)
7. AV D'Amico R Whittington SB Malkowicz, et al. 1999 Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer J Clin Oncol 17 168 172 10458230
8. JI Epstein PC Walsh M Carmichael, et al. 1994 Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 368 374 10.1001/jama.271.5.368 7506797 1:STN:280:DyaK2c7htFalsA%3D%3D (Pubitemid 24037911)
9. CP Nelson RL Dunn JT Wei, et al. 2003 Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions Urol Oncol 21 213 218 12810209
10. SJ Freedland WJ Aronson MK Terris, et al. 2003 Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database J Urol 169 2136 2141 10.1097/01.ju.0000065588.82511.06 12771735 (Pubitemid 36576734)
11. SJ Freedland WJ Aronson GS Csathy, et al. 2003 Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database Urology 61 742 747 10.1016/S0090-4295(02)02525-6 12670558 (Pubitemid 36384966)
12. Y Goto M Ohori A Arakawa, et al. 1996 Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies J Urol 156 1059 1063 10.1016/S0022-5347(01)65702-1 8709307 1:STN:280:DyaK28zitV2lug%3D%3D
13. M Graefen J Noldus U Pichlmeier, et al. 1999 Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics Eur Urol 36 21 30 10.1159/000019922 10364651 1:STN:280:DyaK1M3psVOiug%3D%3D (Pubitemid 29265276)
14. MB Gretzer JI Epstein CR Pound, et al. 2002 Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence Urology 60 1034 1039 10.1016/S0090-4295(02)01997-0 12475665 (Pubitemid 35447562)
15. JI Epstein WC Allsbrook Jr MB Amin, et al. 2005 The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma Am J Surg Pathol 29 1228 1242 10.1097/01.pas.0000173646. 99337.b1 16096414 (Pubitemid 41232997)
16. N Suardi U Capitanio FK Chun, et al. 2008 Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features Cancer 113 2068 2072 10.1002/cncr.23827 18792067
17. SL Conti M Dall'era V Fradet, et al. 2009 Pathological outcomes of candidates for active surveillance of prostate cancer J Urol 181 1628 1633 10.1016/j.juro.2008.11.107 19233388 discussion 1633-1624
18. H Isbarn PI Karakiewicz SA Ahyai, et al. 2009 Differences in histopathological and biochemical outcomes in patients with low Gleason score prostate cancer BJU International 105 818 823 10.1111/j.1464-410X.2009.08841.x 19751264
19. PA Peller DC Young DP Marmaduke, et al. 1995 Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens Cancer 75 530 538 10.1002/1097-0142(19950115)75:2<530::AID-CNCR2820750216>3.0.CO;2-Y 7529129 1:STN:280:DyaK2M7ht1ansA%3D%3D
20. ML Wills J Sauvageot AW Partin, et al. 1998 Ability of sextant biopsies to predict radical prostatectomy stage Urology 51 759 764 10.1016/S0090-4295(98) 00011-9 9610589 1:STN:280:DyaK1c3nt1Whsg%3D%3D (Pubitemid 28261927)
21. H Huland P Hammerer RP Henke, et al. 1996 Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies J Urol 155 1344 1347 10.1016/S0022-5347(01)66262-1 8632570 1:STN:280:DyaK283jtVWksQ%3D%3D (Pubitemid 26081235)
22. RA Badalament MC Miller PA Peller, et al. 1996 An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level J Urol 156 1375 1380 10.1016/S0022-5347(01)65590-3 8808875 1:STN:280:DyaK28vgsVOgtg%3D%3D
23. VS Tigrani V Bhargava K Shinohara, et al. 1999 Number of positive systematic sextant biopsies predicts surgical margin status at radical prostatectomy Urology 54 689 693 10.1016/S0090-4295(99)00211-3 10510929 1:STN:280:DyaK1MvjvV2ntQ%3D%3D (Pubitemid 29449431)
24. V Ravery C Chastang M Toublanc, et al. 2000 Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer Eur Urol 37 449 455 10.1159/000020167 10765076 1:STN:280:DC%2BD3c3ivFKmtw%3D%3D
25. S Conrad M Graefen U Pichlmeier, et al. 1998 Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma J Urol 159 2023 2029 10.1016/S0022-5347(01)63234-8 9598511 1:STN:280:DyaK1c3lvVCmug%3D%3D
26. JH Yoon MH Chen AA Renshaw, et al. 2002 Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate-risk prostate cancer Urology 60 454 457 10.1016/S0090-4295(02)01770-3 12350483 (Pubitemid 35292172)
27. V Ravery LA Boccon-Gibod MC Dauge-Geffroy, et al. 1994 Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy Urology 44 371 376 10.1016/S0090-4295(94)80095-2 7521093 1:STN:280:DyaK2czltlGmsg%3D%3D (Pubitemid 24273820)
28. MM Mortensen PS Mortensen M Borre 2009 Percentage of tumour-positive biopsy cores: an independent predictor of extraprostatic disease Scand J Urol Nephrol 43 109 113 10.1080/00365590802670348 19242861 1:CAS:528: DC%2BD1MXjtVyhurk%3D
29. Y Lotan SF Shariat SM Khoddami, et al. 2004 The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy J Urol 171 2209 2214 10.1097/01.ju.0000127730.78973.fe 15126787 (Pubitemid 38625436)
30. DG Bostwick J Qian E Bergstralh, et al. 1996 Prediction of capsular perforation and seminal vesicle invasion in prostate cancer J Urol 155 1361 1367 10.1016/S0022-5347(01)66267-0 8632575 1:STN:280:DyaK283jtVWkug%3D%3D (Pubitemid 26081240)
31. F Brimo RT Vollmer J Corcos, et al. 2008 Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue Histopathology 53 177 183 10.1111/j.1365-2559.2008.03087.x 18752501 1:STN:280:DC%2BD1crkvVWkug%3D%3D (Pubitemid 352032774)
32. P Harnden MD Shelley B Naylor, et al. 2008 Does the extent of carcinoma in prostatic biopsies predict prostate-specific antigen recurrence? A systematic review Eur Urol 54 728 739 10.1016/j.eururo.2008.06.068 18603352
33. TA Bismar JS Lewis Jr RT Vollmer, et al. 2003 Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population Am J Surg Pathol 27 432 440 10.1097/00000478-200304000-00002 12657927 (Pubitemid 36368540)
34. A Briganti FK Chun GC Hutterer, et al. 2007 Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy Eur Urol 52 733 743 10.1016/j.eururo.2007.02.054 17350750 (Pubitemid 47126152)
35. AV D'Amico R Whittington SB Malkowicz, et al. 2000 Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer J Clin Oncol 18 1164 1172 10715284 (Pubitemid 30159832)
36. AV D'Amico R Whittington SB Malkowicz, et al. 2000 Combination of the preoperative PSA level, biopsy Gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer Urology 55 572 577 10.1016/S0090-4295(99)00479-3 10736506 (Pubitemid 30157966)
37. JC Presti Jr K Shinohara P Bacchetti, et al. 1998 Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy Urology 52 1079 1084 10.1016/S0090-4295(98)00373-2 9836558 (Pubitemid 28533380)
38. G Ploussard E Xylinas L Salomon, et al. 2009 The role of biopsy core number in selecting prostate cancer patients for active surveillance Eur Urol 56 891 1104 10.1016/j.eururo.2009.07.053 19683860
39. SJ Freedland MK Terris GS Csathy, et al. 2004 Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen J Urol 171 2215 2220 10.1097/01.ju.0000124463.13319.0a 15126788 (Pubitemid 38625437)
40. V Ravery HP Schmid M Toublanc, et al. 1996 Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate carcinoma? Cancer 78 1079 1084 10.1002/(SICI)1097-0142(19960901)78:5<1079::AID- CNCR18>3.0.CO;2-# 8780546 1:STN:280:DyaK28znsVamtw%3D%3D (Pubitemid 26284873)
41. PW Linson AK Lee T Doytchinova, et al. 2002 Percentage of core lengths involved with prostate cancer: does it add to the percentage of positive prostate biopsies in predicting postoperative prostate-specific antigen outcome for men with intermediate-risk prostate cancer? Urology 59 704 708 10.1016/S0090-4295(01)01665-X 11992844 (Pubitemid 34461981)
42. OT Okotie WJ Aronson JA Wieder, et al. 2004 Predictors of metastatic disease in men with biochemical failure following radical prostatectomy J Urol 171 2260 2264 10.1097/01.ju.0000127734.01845.99 15126798 (Pubitemid 38625447)
43. H Miyake I Hara T Kurahashi, et al. 2006 Clinicopathological features of patients with biochemical recurrence after radical prostatectomy without progressive rise in serum prostate-specific antigen Urol Int 77 200 204 10.1159/000094809 17033205 1:CAS:528:DC%2BD28XhtVKjtbrE (Pubitemid 44567807)
44. ME Taplin 2003 Biochemical (prostate-specific antigen) relapse: an oncologist's perspective Rev Urol 5 Suppl 3 S3 S13